A once-a-day pill just did something no treatment has ever done in metastatic pancreatic cancer: it nearly doubled how long some patients lived after their first round of chemo failed.
Story Snapshot
- Daraxonrasib extended median survival from about 6.7 to 13.2 months in a major phase 3 trial of previously treated metastatic pancreatic cancer.
- The pill targets RAS gene mutations that drive more than 90% of pancreatic cancers and had long been considered “undruggable.”
- Patients on daraxonrasib not only lived longer but also had better quality of life and fewer severe side effects than with chemotherapy.
- Media headlines about “doubling survival” are real but apply to a specific group of patients, not every pancreatic cancer case.
A deadly cancer finally meets a drug that moves the needle
Pancreatic cancer has earned its grim reputation the hard way: late diagnosis, early spread, and a stubborn resistance to most drugs.
Standard chemotherapy regimens rarely buy more than a few extra months, and for patients whose cancer has already spread and outlived one line of chemo, options dwindle to almost nothing. That is why oncologists took notice when daraxonrasib, an oral targeted drug, showed survival numbers no one had ever seen in this disease before.
The phase 3 RASolute 302 trial focused on patients with metastatic pancreatic cancer whose disease had progressed after at least one prior chemotherapy regimen.[1][3][4]
These patients were randomized to receive either daraxonrasib once daily or the treating physician’s choice of standard second-line chemotherapy.[1][4]
Median overall survival — the point at which half the patients have died — was 13.2 months on daraxonrasib compared with 6.7 months on chemotherapy.[1][3][4] Statistically, that translates to about a 60 percent reduction in the risk of death.[1][3]
What “doubling survival” really means — and what it does not
Television segments and online headlines quickly trumpeted that a “new pill nearly doubles survival” for pancreatic cancer patients.[1][3][4] That phrase is technically accurate for this trial but can be misleading if people assume it applies to every patient at every stage.
The benefit was shown specifically in previously treated metastatic pancreatic ductal adenocarcinoma, a subset that already faces the worst outcomes.[1][3][4][5] No one has proved that daraxonrasib doubles survival in newly diagnosed patients, with local disease, or after surgery.
New pill that doubles pancreatic cancer survival is ‘biggest leap in decades’ for deadly disease https://t.co/SW2ZmY1pVT
— The Sun (@TheSun) May 31, 2026
Careful readers should notice the pattern: broad media framing, narrow clinical reality. This is not a bait-and-switch so much as an enthusiasm gap between journalists and oncologists.
The core signal remains remarkable. In pancreatic cancer trials, gains of two or three months often make it into medical journals.
Seeing survival stretch from roughly seven months to more than thirteen in a randomized phase 3 study justifies calling this a major advance for that specific line of therapy.[1][3][4]
How daraxonrasib hits a once “undruggable” target
At the heart of this story is the RAS gene family, especially KRAS, the genetic engine that drives over 90% of pancreatic ductal adenocarcinomas.[1][3][4][5]
For decades, scientists called KRAS “undruggable” because its shape and biology made it nearly impossible for traditional drugs to latch on.
Daraxonrasib uses a more sophisticated design, acting like molecular glue to bind multiple KRAS subtypes and disrupt the signaling that keeps tumor cells growing.[1][3] This is not old-fashioned poison-the-cell chemotherapy; it is precision sabotage of the tumor’s core circuitry.
The world’s top cancer conference is wrapping up in Chicago today.
Daraxonrasib — a new targeted pill — nearly doubled survival for patients with advanced pancreatic cancer in a Phase 3 trial.
Results: 13.2 months median survival vs 6.7 months with chemotherapy, and fewer side… pic.twitter.com/pJeZx0AXM7
— Vitamvivere (@Vitamvivere) June 2, 2026
Early-phase data published in a major medical journal already showed that daraxonrasib could shrink tumors and produce durable responses in patients with various RAS-mutated advanced cancers.[5] Those signals laid the groundwork for testing the drug head-to-head against chemotherapy in RASolute 302.
Taken together, the data support the idea that this drug is not a fluke: it consistently shows biologic activity where nearly everything else has failed.[4][5] That is part of why some specialists now describe it as a potential new standard of care after first-line chemotherapy.[1][4]
Side effects, quality of life, and what patients actually feel
Survival statistics matter, but what life looks like during those extra months matters more. Patients on daraxonrasib used the pill for significantly longer than control patients stayed on chemotherapy and reported less pain and better overall quality of life.[1][3]
Severe side effects still occurred — notably rash and painful mouth sores — but fewer patients had to stop treatment because of toxicity compared to chemotherapy.[1][3][5] That balance lines up with basic conservative instincts in medicine: longevity only counts if life remains livable.
Trial investigators emphasized that the drug’s benefit extended across the trial population, not only in a narrow genetic niche, even though it was designed to target the KRAS pathway.[1][3][4]
Because most pancreatic cancers harbor KRAS mutations, the potential eligible population is large. Yet prudence requires another reminder: these results come from people who were strong enough to receive and then fail at least one prior chemotherapy regimen.[1][3][4] Frailer patients, or those with rapidly exploding disease, may not see the same benefit.
Where this leaves patients, families, and the system
For families living under the shadow of pancreatic cancer, the daraxonrasib data offer something that has been scarce for decades: credible hope backed by rigorous randomized evidence.
The lead researchers argue that daraxonrasib should become a new standard of care in previously treated metastatic disease and are already planning trials earlier in the disease course, including before surgery to see if tumor shrinkage might make more patients operable.[1][3][4] Regulators have granted early access mechanisms while formal review proceeds.[3][5]
From a policy and values perspective, this is the kind of innovation Americans want the system to reward: a targeted therapy that extends life, improves quality of life, and emerges from transparent clinical testing rather than political hype.
The challenge ahead will be ensuring access without allowing pricing or exaggerated marketing to outrun the actual evidence. For now, daraxonrasib stands as a rare good news story in a cancer type that has not had many — a proof that once “impossible” targets can, eventually, be cracked.[1][3][4][5]
Sources:
[1] Web – New drug nearly doubles survival rates in some pancreatic cancer …
[3] Web – How Did Daraxonrasib Double Survival in Pretreated Metastatic …
[4] Web – First RAS Inhibitor Extends Survival in Previously Treated Metastatic …
[5] Web – Daraxonrasib in Previously Treated Advanced RAS-Mutated …
